PRESS RELEASES
Stemedica Begins First Clinical Trials In The U.S. Using Adult Allogeneic Stem Cells To Treat Alzheimer’s Disease
Initial Sites Are Emory University and University of California, Irvine SAN DIEGO, California, and Lausanne, Switzerland — July 27, 2016 — Stemedica Cell Technologies, Inc. and its subsidiary, Stemedica International S.A., a leader in the development of innovative...
FDA Grants IND Approval To Stemedica For A Traumatic Brain Injury Phase IIa Clinical Trial
Stemedica received an FDA investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its ischemic tolerant, adult allogeneic mesenchymal stem-cells (itMSC) to treat subjects with traumatic brain injury (TBI).
Stemedica Cell Technologies Announces Completion of Enrollment in Phase I/IIA Clinical Trial for Ischemic Stroke
Stemedica announced completion of enrollment into “A Phase I/IIa, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects with Ischemic Stroke.”
Stemedica Establishes Stem Cell Commercial Manufacturing Facility
Stemedica expands manufacturing capacity for Phase III and commercial stem cell products San Diego, California and Epalinges, Switzerland – November 10, 2015 – Stemedica Cell Technologies, Inc., a leading manufacturer of adult, allogeneic stem cells and preserved stem...
Stemedica Awarded US Patent for Transgenic Therapeutic Stem Cells
Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, received United States Patent No. 9080184 entitled “Transgenic Therapeutic Stem Cells and Methods for Their Use and Manufacture.” The patent issued on July...
Stemedica Earns US Patent for Cellular Scaffold Enhanced by Stem Cell Factors
Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, received a new patent from the U.S. Patent & Trademark Office, US8709081 entitled “Cellular Scaffold.” This patent, coupled with the US8105380 patent...
FDA Grants IND Approval for Phase IIa Clinical Trial Using Stemedica’s ITMSC Therapy to Treat Alzheimer’s Disease
Planned to Launch in the Fourth Quarter 2015 in the United States as the First Alzheimer’s Clinical Trial Using Intravenous Administration of Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) SAN DIEGO and Epalinges, Switzerland — June 9, 2015 — Stemedica Cell...
Stemedica Obtains an Exclusive Worldwide License for Stem Cell Stabilization and Preservation Technologies
Commercial-scale Preservation of Therapeutically-active Stem Cell-derived Products For Worldwide Marketplace Opportunities SAN DIEGO—March 24, 2015—Stemedica Cell Technologies Inc., (Stemedica), announced today that Universal Stabilization Technologies (UST) has...
Stemedica Issued US Patent Method for Identifying Neuripotent Cells
Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors, announced today that the Company has been issued Patent No. US 8,642,286 B2 entitled, Methods for Identifying Neuripotent Cells by the United States Patent...
President of Leading South Korean Biopharmaceutical Company Green Cross Holdings Joins Stemedica’s Board of Directors
Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, welcomes Byung-Geon “BG” Rhee, Ph.D., President of Green Cross Holdings, a South Korean biopharmaceutical company, to its board of directors. Green Cross,...